» Download Public Reports
About 200 reports
- Country report
- December 2012
- 8 pages
... Mass [13], and in addition, fat distribution may be more important for cardiovascular diseases. However, the question whether wc is more strongly associated with cardiovascular risk than bmi in children ...
December 2012
... Manufacturing and commercialization of unique gelatin-based dosage forms. Banner has developed several patent-pending drug delivery platforms, including those that enhance and control the absorption of poorly ...
December 2012
... The group S drug cands may not obtain regulatory approval when expected, if at all, and even after obtaining approval, the drugs will be subject to ongoing regulation. To date, none of the group S drug ...
December 2012
... Regulatory approval and commence product sales as currently contemplated. The group S drug cands may not obtain regulatory approval when expected, if at all, and even after obtaining approval ...
December 2012
... pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Over the last fiscal year the company generated revenues of over $2.0 Billion. Through its three businesses ...
December 2012
... Ltd. (Nyse: rdy) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Over the last fiscal year the company generated ...
January 2013
... Opportunities robust growth in hnh (* excl. Personal care and citric acid divestment) hnh sales driven by all segments and regions dietary supplements growth in premix for multivitamins, omega-3 S, vitamin ...
» Purchase Premium Reports
(From $ 250 - $ 2 000)
About 200 reports
- $ 2 000
- Company report
- March 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Actinic Keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...
March 2013
$ 1 088
BMI View: While the Netherlands is a low risk industry from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western Europe ...
April 2013
$ 1 050
Includes 3 FREE quarterly updates Core Views The Dutch economy's growth outlook is set to seriously deteriorate in the coming quarters, as the eurozone sovereign debt crisis massively weighs on economic ...
May 2013
$ 652
This market research report offers a perspective on the actual market situation, trends and future outlook for vaccines in Netherlands. The study provides essential market information for decision-makers ...
April 2013
$ 500
Synopsis Timetric's 'Chemical & Pharmaceutical Plant Construction in the Netherlands to 2017: Market Databook' contains detailed historic and forecast market value data for the chemical & pharmaceutical ...
March 2013
$ 300
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...
March 2013
$ 300
Summary ARKOPHARMA Laboratories (Arkopharma) is phytotherapy and nutritional supplements provider in Europe, engaged in the manufacture and distribution of pharmaceutical products. Its product portfolio ...